ATE123291T1 - Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente. - Google Patents

Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.

Info

Publication number
ATE123291T1
ATE123291T1 AT88907884T AT88907884T ATE123291T1 AT E123291 T1 ATE123291 T1 AT E123291T1 AT 88907884 T AT88907884 T AT 88907884T AT 88907884 T AT88907884 T AT 88907884T AT E123291 T1 ATE123291 T1 AT E123291T1
Authority
AT
Austria
Prior art keywords
permeability
biologically active
killing
fragments
protein fragments
Prior art date
Application number
AT88907884T
Other languages
English (en)
Inventor
Peter Elsbach
Jerrold Weiss
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26770870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE123291(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE123291T1 publication Critical patent/ATE123291T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742Bactericidal/Permeability-increasing protein [BPI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751Bactericidal/permeability-increasing protein [BPI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Noodles (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT88907884T 1987-08-11 1988-08-09 Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente. ATE123291T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8433587A 1987-08-11 1987-08-11
US22803588A 1988-08-05 1988-08-05

Publications (1)

Publication Number Publication Date
ATE123291T1 true ATE123291T1 (de) 1995-06-15

Family

ID=26770870

Family Applications (2)

Application Number Title Priority Date Filing Date
AT88907884T ATE123291T1 (de) 1987-08-11 1988-08-09 Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
AT94115703T ATE312844T1 (de) 1987-08-11 1988-08-09 Biologisch-aktive bakterizide/permeabilitätserhöhende proteinbruchstücke

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94115703T ATE312844T1 (de) 1987-08-11 1988-08-09 Biologisch-aktive bakterizide/permeabilitätserhöhende proteinbruchstücke

Country Status (7)

Country Link
US (1) US5980897A (de)
EP (3) EP1659132A1 (de)
JP (1) JP3086685B2 (de)
AT (2) ATE123291T1 (de)
CA (1) CA1341525C (de)
DE (2) DE3853918T2 (de)
WO (1) WO1989001486A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6093801A (en) * 1989-02-14 2000-07-25 Incyte Pharmaceuticals, Inc. Recombinant analogs of bactericidal/permeability increasing protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5652211A (en) * 1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A
SE468516B (sv) * 1991-06-14 1993-02-01 Kabigen Ab Nya polypeptider vilka kan utvinnas fraan tunntarmen och deras anvaendning
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性/浸透性増大タンパク質(Bactericidal/Permeability Increasing protein:BPI)及び界面活性剤を含有する医薬組成物
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
WO1995005393A2 (en) * 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
JP2000511190A (ja) * 1996-05-23 2000-08-29 ゾーマ コーポレイション 外傷に起因する出血に見舞われたヒトにおけるbpiタンパク質産物の治療用途
EP0939766A2 (de) 1996-05-24 1999-09-08 The Regents Of The University Of Minnesota Synthese von löslichen beta-sheet bildenden peptiden
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6153584A (en) 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US7041644B2 (en) 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
AU2001252246A1 (en) * 2000-04-05 2001-10-23 Syngenta Participations Ag Therapeutically active proteins in plants
KR100351829B1 (ko) * 2000-09-26 2002-09-11 엘지전자 주식회사 디지털 통신 시스템
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Bpiタンパク質産物またはbpiインヒビターを使用する、周皮細胞増殖の調節
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
EP1741440A1 (de) * 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
CN103648515B (zh) 2011-04-05 2018-01-02 达纳-法伯癌症研究所有限公司 作为辐射缓和剂和辐射防护剂的bpi和其同源物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein

Also Published As

Publication number Publication date
EP0375724B1 (de) 1995-05-31
WO1989001486A1 (en) 1989-02-23
EP0375724A1 (de) 1990-07-04
JP3086685B2 (ja) 2000-09-11
DE3853918D1 (de) 1995-07-06
ATE312844T1 (de) 2005-12-15
JP2000139484A (ja) 2000-05-23
DE3856588D1 (de) 2006-01-19
EP0375724A4 (en) 1991-12-11
EP1659132A1 (de) 2006-05-24
US5980897A (en) 1999-11-09
EP0652230B1 (de) 2005-12-14
CA1341525C (en) 2007-04-17
DE3856588T2 (de) 2006-09-07
EP0652230A1 (de) 1995-05-10
DE3853918T2 (de) 1996-02-08

Similar Documents

Publication Publication Date Title
ATE123291T1 (de) Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
ATE98260T1 (de) Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins.
FI974432A7 (fi) Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE3884529D1 (de) Leader-anteile zur produktion von rekombinanten proteinen.
NO874908D0 (no) Antimikrobielle proteiner, preparater inneholdende disse og anvendelse derav.
AU9127591A (en) Biologically active bactericidal/permeability-increasing protein fragments
IL68366A0 (en) Preparation of functional human urokinase proteins
NO865191L (no) Gm-csf-protein, derivater derav og fremstilling og anvendelse av slike proteiner.
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
FI885237A7 (fi) Menetelmä yhdistelmä-E. colissa ilmennetyn P. falciparum-CS-proteiinir okotteen eristämiseksi ja puhdistamiseksi
SE8505920D0 (sv) New protein and its use
FI893932A7 (fi) Funktionaalisten homologisten ja heterologisten proteiinien ilmaiseminen E.colin ja muiden gram-negatiivisten bakteerien ulkomembraanilla
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
EP0723016A3 (de) Leukocyten-aktivierender Faktor
FI901764A7 (fi) Synteettinen DNA-sekvenssi, joka koodaa ihmisen insuliinin kaltaista k asvutekijää II
FI881870A7 (fi) L-fenyylialaniinin valmistus rekombinanttibakteerien avulla.
FI924835L (fi) Pectinatus-bakteerin proteiinifragmentteja
DE59009360D1 (de) Für das Plazentaprotein 9 (PP9) kodierende cDNA, ihre Isolierung und Verwendung.
NO875477D0 (no) Rekombinant alveolaert overflateaktivt protein.
IT8621261A0 (it) Composizioni farmaceutiche per la terapia di stati fisiopatologici ad accresciuto catabolismo proteico.
NZ212039A (en) Vaccine containing bacteria capable of living on protein foreign to warm-blooded animals
ITMI961647A1 (it) Uso di particolari specie di batteri lattici o loro miscele per l'autopurificazione fisiologica della vagina e composizioni farmaceutiche che le contengono.
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.
ATE95238T1 (de) Leader-anteile zur produktion von rekombinanten proteinen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee